The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 2.25 — grey zone — between safe and distressedWatch
Where the revenue comes from
Fiscal 2025, as Royalty Pharma plc reports it. History and quarterly detail are in the app.
- Income from financial royalty assets$2.3B
- Other royalty income and revenues$117.0M
Leadership changes
From Royalty Pharma plc's own filings, the day they're filed.
- Arthur R. McGivern · President · appointmenteff. 2025-12-31
- Henry Fernandez · Directors · departureeff. 2025-08-13
- Carole Ho · Directors · appointmenteff. 2025-07-17
Latest filings
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-08-05
- 8-K · Company announcement2026-06-04
- 8-K · Company announcement2026-05-28
- 10-Q · Quarterly report2026-05-06
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Royalty Pharma plc, every answer cited to the official filings🔒
- The Intelligence Brief — added when Royalty Pharma plc's brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.